Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1Phase 1/2 1

Status

Recruiting 4Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 4

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 6Recurrence 1Neoplasms, Plasma Cell 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × elotuzumab × 90 days × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06158841 2026-06-05

CERVINO

AbbVie

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

NCT06208150 2026-06-05

MonumenTAL-6

Janssen Research & Development, LLC

Phase 3 Recruiting
795 enrolled
Plasma cell

Multiple Myeloma

NCT07555938 2026-05-27

CEVOLUTION

Hoffmann-La Roche

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Bristol-Myers Squibb

Phase 2 Completed
67 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡